C

Cheiron

AI-powered OS for drug programs

Technical Product Management Intern

Internship
$35 - $55/hr
Bachelor's
Los Altos, CA, USA
In PersonFully in-person in the Los Altos office. Relocation support may be available case by case.
ProductTechnical Product Management

About the job

Requirements
  • A strong technical foundation, including the ability to read a codebase, reason about system architecture, and ground a specification in the existing system; a degree in computer science, engineering, or a related technical field.
  • Experience producing structured technical documents that others can build from, such as design documents, specifications, architecture proposals, research papers, or detailed project writeups.
  • Clear personal ownership of work, including the ability to explain defined scope, decisions and tradeoffs, and potential improvements.
  • Fluency with AI tools such as Claude Code, Cursor, or equivalent, and use of them as a natural part of the work.
  • Initiative, sound judgment, and comfort working through ambiguous problems in a fast-moving environment.
  • Semester- or quarter-term interns must be available at least 20 hours per week; co-op and summer interns should be available full time.
Responsibilities
  • Break product briefs into components, define relationships and boundaries with the product team and domain experts, and scope what goes into the build.
  • Write numbered feature stories with acceptance criteria, edge cases, and state transitions that an engineer can pick up cold.
  • Review data models and API contracts against the existing schema; identify what to extend, what to refactor, and what to leave alone.
  • Define correctness for AI-driven features, including document extraction, regulatory classification, and compliance state derivation.
  • Run specifications through review with engineering and the life sciences team before handoff, and resolve ambiguity during the build.
  • Work directly with founders, engineers, and domain experts, demonstrate progress frequently, and make pragmatic scope decisions.
Desired Qualifications
  • Experience with healthcare, life sciences, regulated industries, or AI-native products is a plus but not required.

About the company

Cheiron builds an AI-native operating system for drug programs centered on a Life Sciences Knowledge Graph that connects biomedical, clinical, regulatory, patent and commercial data. The product organizes live data into a graph that tracks claims, evidence, assumptions, risks, decisions and commitments to support workflows across clinical, regulatory, and strategic decisions. It differentiates itself by providing an integrated, live knowledge-graph backbone rather than siloed papers, enabling cross-domain inferences and faster decision making. Its goal is to speed and improve drug development by delivering a continually updated, connected view of relevant information to guide design, regulatory strategy, and business decisions.

Company Size

11-50

Company Stage

Seed

Total Funding

$12M

Headquarters

Los Altos, California

Founded

2024

Get referred to Cheiron

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cheiron launched SOC 2 Type II and ISO 27001, reducing enterprise procurement friction.
  • Open roles in Los Altos and Seoul show active hiring across product and engineering.
  • Active pilots with global pharmaceutical companies create a near-term path to U.S. revenue.

What critics are saying

  • BenchSci and Veeva already own enterprise biotech workflows; Cheiron faces fast incumbent retaliation.
  • Cheiron's credibility depends on source-grounded outputs; one bad regulatory answer kills trust by 2027.
  • If U.S. expansion stalls after the 2026 seed, Cheiron remains a Korea-first niche product.

What makes Cheiron unique

  • Cheiron models entire drug programs, not isolated tasks, using its Life Sciences Knowledge Graph.
  • Menlo Ventures backed Cheiron on July 22, 2026, signaling credible investor conviction.
  • Cheiron already sells to seven of Korea's top 10 biopharma companies.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Meal Benefits
  • Commuter Benefits

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

0%

2 year growth

0%
Menlo Ventures
Jul 22nd, 2026
A unified OS for drug development: our investment in Cheiron.

A unified OS for drug development: our investment in Cheiron. July 22, 2026 Drug development is one of the hardest problems in the world. It takes a decade, costs billions, and fails 90% of the time. Much of this is a natural consequence of how complex these programs are. A drug in development touches clinical, regulatory, manufacturing, and commercial functions all at once, generating knowledge across each that rarely makes its way into a single shared picture. Even the most talented scientists and program leads end up spending a significant amount of their time hunting down context rather than acting on it. The result is slower timelines, decisions made on incomplete information, and drugs that take longer to reach the patients who need them. This is the problem the Cheiron team set out to solve. Today, we're thrilled to announce Cheiron's $8 million seed round, led by Menlo Ventures, with the backing and strategic support of industry veterans including Moderna co-founder and MIT Institute Professor Robert Langer; former Pfizer Chief Medical Officer Freda Lewis-Hall; Chai Discovery co-founder and CEO Josh Meier; former Starbucks CEO Laxman Narasimhan; and former Apple AI chief John Giannandrea. A drug program, represented as a whole. If we look at what it takes to advance a drug program, at any given moment, a team is simultaneously tracking efficacy signals, monitoring the safety profile, stress-testing the regulatory strategy against precedent, and watching competitors for anything that might invalidate their assumptions. At the heart of this is a single argument - that this molecule treats this disease, safely and effectively - which has to hold up at every stage and is being made across dozens of people, hundreds of documents, and years of accumulated context. Yet none of it is connected. Cheiron built the infrastructure to piece it all together. The platform's Lifesciences Knowledge Graph (LKG) ingests and structures biomedical, clinical, regulatory, patent, and commercial knowledge, then maps it against the specific contours of a customer's program. The result is a drug program you can actually query. For the first time, teams have a single place to see the full state of their program and stress-test it in real time. Is the safety narrative still consistent with the latest data? Does the trial design hold up against recent regulatory precedent? Are there gaps in the evidence package that need to be closed before a submission? Cheiron holds the state of the program so experts can focus on judgment, and every answer is traceable to a source and defensible in a room full of scientists. Cheiron's early traction speaks for itself. In less than six months since launch, the platform has reached more than 20% of Korea's biopharma knowledge-worker base and secured seven of the country's top 10 biopharma companies as customers. Building on this momentum, Cheiron is now running active pilots with leading global pharmaceutical companies as it expands into the U.S. market. A customer-obsessed team. The best founders understand their customers at a level that borders on obsessiveness, and Minseok Bae, Jason Park, and Harshit Gupta have that quality in abundance. They met at Stanford and bring extraordinary technical pedigree across competitive programming, biology, and physics, but what stayed with us after our first meeting was how clearly they saw the problem from the customer's seat, and how relentlessly they'd already moved to solve it. The team has also assembled a deep advisor bench of industry veterans across pharma who have led FDA approvals and built global drug programs from the ground up. Backing the Future of AI and Biology. At Menlo, we've long believed that one of AI's most transformative applications lies at the intersection of AI and biology. Cheiron joins a portfolio we've been deliberately building at this intersection, including Chai Discovery, which is developing foundation models for biology, Phylo, building an IDE for biological design, and Aurora Therapeutics, developing therapies for rare diseases. We're thrilled to welcome Minseok, Jason, Harshit, and the Cheiron team to the Menlo family.

StreetInsider
Jul 22nd, 2026
Cheiron raises $8M led by Menlo Ventures to build AI operating system for drug development

Cheiron, a Los Altos-based startup building an operating system for drug development programs, has raised $8 million in seed funding led by Menlo Ventures. The round included backing from notable industry figures including Moderna co-founder Robert Langer, former Pfizer Chief Medical Officer Freda Lewis-Hall, and former Apple AI chief John Giannandrea. The company's platform uses AI to model drug programs as connected systems, consolidating scattered information from experiments, clinical results, regulatory interactions, and scientific literature. At its core is the Life Sciences Knowledge Graph, which structures biomedical, clinical, regulatory, patent, and commercial knowledge into a single model. Since launching less than six months ago, Cheiron has been adopted by tens of thousands of biopharma professionals. The funding will support expansion of the platform's capabilities across clinical, regulatory, and strategic workflows, and grow the company's engineering and life sciences teams.

VCNewsDaily
Aug 4th, 2025
PhnyX Lab Raises $4M SAFE Round

PhnyX Lab, a GenAI startup, has successfully closed a $4M seed round through a Simple Agreement for Future Equity (SAFE).

PR Newswire
Aug 4th, 2025
AI startup PhnyX Lab secures $4 million in funding round led by SK Networks, with participation from Aidan Gomez, Illia Polosukhin, and other notable angel investors

/PRNewswire/ -- PhnyX Lab, a pioneering GenAI startup transforming how life science companies operate, announced the successful close of a $4 million seed...